Parkinson’s Disease Therapeutics Market Research Report- Forecast to 2027

Parkinson’s Disease Therapeutics Market: Treatment Type (Medication and Surgical Therapy (Deep Brain Stimulation (DBS) and Carbidopa/Levodopa Enteral Suspension), End-User (Hospitals & Clinics, Academic & Industrial Research) - Forecast Till 2027

ID: MRFR/Pharma/1043-HCR | February 2021 | Region: Global | 90 Pages         

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Parkinson’s disease Therapeutics Market, by Treatment Type

6.1 Introduction

6.2 Medications

6.2.1 Dopamine Precursors

6.2.2 Peripheral Decarboxylase Inhibitors

6.2.3 COMT Inhibitors

6.2.4 MAO Inhibitors

6.2.5 Others

6.3 Surgical Therapy

6.3.1 Deep Brain Stimulation (DBS)

6.3.2 Carbidopa/Levodopa Enteral Suspension

Chapter 7. Global Parkinson’s disease Therapeutics Market, by End-User

7.1 Introduction

7.2 Hospitals & Clinics

7.3 Academic & Industrial Research

7.4 Others

Chapter 8. Global Parkinson’s disease Therapeutics Market, by Region

8.1 Introduction

8.2 America

8.2.1 North America

8.2.1.1 U.S.

8.2.1.2 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 U.K.

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 Republic of Korea

8.4.6 Rest of Asia Pacific

8.5 The Middle East & Africa

8.5.1 United Arab Emirates

8.5.2 Saudi Arabia

8.5.3 Oman

8.5.4 Kuwait

8.5.5 Qatar

8.5.6 Rest of the Middle East & Africa

Chapter 9. Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

9.3.1 Key Developments

Chapter 10 Company Profiles

10.1 Salix Pharmaceuticals

10.1.1 Company Overview

10.1.2 Type Overview

10.1.3 Financials

10.2.4 Key Developments

10.1.5 SWOT Analysis

10.2 GlaxoSmithKline Plc

10.2.1 Company Overview

10.2.2 Type Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Impax Laboratories, LLC

10.3.1 Company Overview

10.3.2 Type Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Teva Pharmaceutical Industries Ltd

10.4.1 Company Overview

10.4.2 Type/Business Segment Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Novartis AG

10.5.1 Company Overview

10.5.2 Type Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 Orion Corporation

10.6.1 Company Overview

10.6.2 Type Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Mylan N.V.

10.7.1 Overview

10.7.2 Type Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Par Pharmaceutical

10.8.1 Overview

10.8.2 Type Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.9 Cipla Inc.

10.9.1 Overview

10.9.2 Type Overview

10.9.3 Financials

10.9.4 Key Developments

10.9.5 SWOT Analysis

10.10 Daiichi Sankyo

10.10.1 Overview

10.10.2 Type Overview

10.10.3 Financials

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.11 Apotex Inc.

10.11.1 Overview

10.11.2 Type Overview

10.11.3 Financials

10.11.4 Key Developments

10.11.5 SWOT Analysis

10.12 Wockhardt Limited

10.12.1 Overview

10.12.2 Type Overview

10.12.3 Financials

10.12.4 Key Developments

10.12.5 SWOT Analysis

10.13 ACADIA Pharmaceuticals Inc

10.13.1 Overview

10.13.2 Type Overview

10.13.3 Financials

10.13.4 Key Developments

10.13.5 SWOT Analysis

10.14 Abbott

10.14.1 Overview

10.14.2 Type Overview

10.14.3 Financials

10.14.4 Key Developments

10.14.5 SWOT Analysis

10.15 Others

Chapter 11 Appendix


LIST OF TABLES

Table 1 Global Parkinson’s disease Therapeutics Market Industry Synopsis, 2020-2027

Table 2 Global Parkinson’s disease Therapeutics Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Global Parkinson’s disease Therapeutics Market, by Region, 2020-2027, (USD Million)

Table 4 Global Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 6 Global Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)

Table 7 North America Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 9 North America Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)

Table 10 U.S. Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 11 U.S. Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)

Table 12 Canada Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 13 Canada Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)

Table 14 South America Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 15 South America Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)

Table 16 Europe Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 17 Europe Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)

Table 18 Western Europe Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 19 Western Europe Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)

Table 20 Eastern Europe Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 21 Eastern Europe Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)

Table 22 Asia Pacific Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 23 Asia Pacific Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)

Table 24 The Middle East & Africa Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)

Table 25 The Middle East & Africa Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Parkinson’s disease Therapeutics Market

Figure 3 Market Dynamics for Global Parkinson’s disease Therapeutics Market

Figure 4 Global Parkinson’s disease Therapeutics Market Share, by Treatment Type, 2020

Figure 5 Global Parkinson’s disease Therapeutics Market Share, by End-User, 2020

Figure 6 Global Parkinson’s disease Therapeutics Market Share, by Region, 2020

Figure 7 North America Parkinson’s disease Therapeutics Market Share, by Country, 2020

Figure 8 Europe Parkinson’s disease Therapeutics Share, by Country, 2020

Figure 9 Asia Pacific Parkinson’s disease Therapeutics Market Share, by Country, 2020

Figure 10 The Middle East & Africa Parkinson’s disease Therapeutics Market Share, by Country, 2020

Figure 11 Global Parkinson’s disease Therapeutics Market: Company Share Analysis, 2020 (%)

Figure 12 Abbott: Key Financials

Figure 13 Abbott: Segmental Revenue

Figure 14 Abbott: Geographical Revenue

Figure 15 Salix Pharmaceuticals: Key Financials

Figure 16 Salix Pharmaceuticals: Segmental Revenue

Figure 17 Salix Pharmaceuticals: Geographical Revenue

Figure 18 GlaxoSmithKline Plc: Key Financials

Figure 19 GlaxoSmithKline Plc: Segmental Revenue

Figure 20 GlaxoSmithKline Plc: Geographical Revenue

Figure 21 Impax Laboratories, LLC: Key Financials

Figure 22 Impax Laboratories, LLC: Segmental Revenue

Figure 23 Impax Laboratories, LLC: Geographical Revenue

Figure 24 Teva Pharmaceutical Industries Ltd: Key Financials

Figure 25 Teva Pharmaceutical Industries Ltd: Segmental Revenue

Figure 26 Teva Pharmaceutical Industries Ltd: Geographical Revenue

Figure 27 Novartis AG: Key Financials

Figure 28 Novartis AG: Segmental Revenue

Figure 29 Novartis AG: Geographical Revenue

Figure 30 Orion Corporation: Key Financials

Figure 31 Orion Corporation: Segmental Revenue

Figure 32 Orion Corporation: Geographical Revenue

Figure 33 Mylan N.V.: Key Financials

Figure 34 Mylan N.V.: Segmental Revenue

Figure 35 Mylan N.V.: Geographical Revenue

Figure 36 Par Pharmaceutical: Key Financials

Figure 37 Par Pharmaceutical: Segmental Revenue

Figure 38 Par Pharmaceutical: Geographical Revenue

Figure 39 Cipla Inc.: Key Financials

Figure 40 Cipla Inc.: Segmental Revenue

Figure 41 Cipla Inc.: Geographical Revenue

Figure 42 Daiichi Sankyo: Key Financials

Figure 43 Daiichi Sankyo: Segmental Revenue

Figure 44 Daiichi Sankyo: Geographical Revenue

Figure 45 Apotex Inc.: Key Financials

Figure 46 Apotex Inc.: Segmental Revenue

Figure 47 Apotex Inc.: Geographical Revenue

Parkinson’s disease therapeutics market

Parkinson’s Disease Therapeutics Market valued at around USD 5.18 billion and is projected to grow at more than 6.8% CAGR during the forecast period

Segmentation

By Treatment Type Medication Surgical Therapy Carbidopa/Levodopa Enteral Suspension
By End-User Hospitals & Clinics Academic & Industrial Research

Key Players

  • Salix Pharmaceuticals
  • GlaxoSmithKline Plc
  • Impax Laboratories LLC
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Orion Corporation
  • Mylan N.V.
  • Par Pharmaceutical
  • Cipla Inc.
  • Daiichi Sankyo

Drivers

  • Increasing number of healthcare organizations
  • Increasing prevalence of geriatric population
Speak to Analyst Request a Free Sample

Market Scenario


Globally the Parkinson’s disease therapeutics market is increasing rapidly. The major factor that drives the growth of the Parkinson’s disease therapeutics market is the increasing growth in aging population. Furthermore, increasing environmental factors & genetic heredity is increasing the growth of the Parkinson’s disease therapeutics market. Moreover, the risk of Parkinson’s disease increases with age, and the disease mainly affects a person over 50 years of age. The treatments for the Parkinson’s disease are mainly symptomatic and no curative treatment options.


However, expiration of patent drugs is expected to hamper the Parkinson’s disease therapeutics market growth during the forecast period.


Research Methodology


Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global Parkinson’s disease therapeutics market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.


Parkinson’s disease Therapeutics Market, by Key Players



  • Salix Pharmaceuticals

  • GlaxoSmithKline Plc

  • Impax Laboratories, LLC

  • Teva Pharmaceutical Industries Ltd

  • Novartis AG, Orion Corporation

  • Mylan N.V.

  • Par Pharmaceutical

  • Cipla Inc.

  • Daiichi Sankyo

  • Apotex Inc.

  • Wockhardt Limited


Segmentation


The Parkinson’s disease therapeutics market is segmented on the basis of treatment type and end-user.  The Parkinson’s disease therapeutics market by treatment type is segmented into medication and surgical therapy. Medication segment is segmented further into dopamine precursors, peripheral decarboxylase inhibitors, COMT inhibitors, MAO inhibitors, and others. Surgery therapy is further segmented into deep brain stimulation (DBS) and carbidopa/levodopa enteral suspension. 


On the basis of end-user, the Parkinson’s disease therapeutics market is categorized into hospitals & clinics, academic & industrial research, and others.


On the basis of region, the global Parkinson’s disease therapeutics market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Regional Market Summary


Parkinson’s Disease Therapeutics Market Share (%), by Region, 2017


 Parkinson’s Disease Therapeutics Market Share


Sources: National Electronic Health Records Survey, U.S. Department of Health & Human Services, National Center for Health Statistics


The Parkinson’s disease therapeutics market is dominated by North America owing to the rising healthcare expenditure that contributes to enhancing the market growth in this region. According to Parkinson Association of the Carolinas, approximately 60,000 Americans are diagnosed with Parkinson’s disease each year.


It is estimated that Europe stood second in the global Parkinson’s disease therapeutics market. Rising government initiatives to promote the healthcare sector and increased adoption of research and development activities for chronic diseases in the healthcare domain drive the market in this region. Moreover, the entry of market leaders into strategic partnerships and collaborations with the chemical industry contribute to the growth of the Parkinson’s disease therapeutics market in Europe.


Asia Pacific is likely to witness growth in the Parkinson’s disease therapeutics market during the forecast period owing to the increasing number of healthcare organizations, increasing prevalence of Parkinson’s disease. Moreover, increasing prevalence of geriatric population in the region influence the Parkinson’s disease therapeutics market growth. China, India, and Japan are the key market players in this region, and Asia Pacific is expected to be the fastest growing market for the Parkinson’s disease therapeutics.


The Middle East and Africa holds the least share in the global Parkinson’s disease therapeutics market due to the presence of stringent government policies and poor economies.


Market Segmentation and Key Market Players


Parkinson’s disease Therapeutics Market, by Treatment Type



  • Medications

    • Dopamine Precursors

    • Peripheral Decarboxylase Inhibitors

    • COMT Inhibitors

    • MAO Inhibitors

    • Others



  • Surgical Therapy

    • Deep Brain Stimulation (DBS)

    • Carbidopa/Levodopa Enteral Suspension




Parkinson’s disease Therapeutics Market, by End-user



  • Hospitals & Clinics

  • Academic & Industrial Research

  • Others


Parkinson’s disease Therapeutics Market, by Region



  • The Americas

  • Europe

  • Asia Pacific

  • The Middle East & Africa


Intended Audience



  • Contract Research Organizations (CROs)

  • Academic Medical Institutes and Universities

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Market research and consulting service providers



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2020-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   20202-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Treatment Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Salix Pharmaceuticals, GlaxoSmithKline Plc, Impax Laboratories, LLC, Teva Pharmaceutical Industries Ltd, Novartis AG, Orion Corporation, Mylan N.V., Par Pharmaceutical, Cipla Inc., Daiichi Sankyo, Apotex Inc., Wockhardt Limited
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing growth in aging population
  • Increasing environmental factors & genetic heredity


  • Speak to Analyst Ask for Customization